

# Involvement of LFA-1 in Lymphoma Invasion and Metastasis Demonstrated with LFA-1-deficient Mutants

Folkert F. Roossien, Diana de Rijk, Annelies Bikker, and Ed Roos

Division of Cell Biology, Antoni van Leeuwenhoekhuis, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

**Abstract.** Lymphocyte function-associated antigen-1 (LFA-1) is a leukocyte and lymphoma cell surface protein that promotes intercellular adhesion. We have previously shown that the invasion of hepatocyte cultures by lymphoma cells is inhibited by anti-LFA-1 antibodies (Roos, E., and F. F. Roossien. 1987. *J. Cell Biol.* 105:553-559). In addition, we now report that LFA-1 is also involved in invasion of lymphoma cells into fibroblast monolayers.

To investigate the role of LFA-1 in metastasis of these lymphoma cells, we have generated mutants that

are deficient in LFA-1 cell surface expression because of impaired synthesis of either the  $\alpha$  or  $\beta$  subunit precursor of LFA-1. We identified at least three distinct mutant clones. The invasive potential of the mutant cells in vitro, in both hepatocyte and fibroblast cultures, was considerably lower than that of parental cells.

The metastatic potential of the mutants was much reduced, indicating that LFA-1 expression is required for efficient metastasis formation by certain lymphoma cells.

**W**HEN metastatic tumor cells invade tissues from the blood they have to adhere to both extracellular matrix and cells in those tissues. Since extracellular matrix is scarce in the liver, adhesion to cells is probably the most important. Certain lymphomas readily metastasize to the liver and invade extensively between hepatocytes. Such lymphoma cells are highly invasive in cultures of isolated hepatocytes (Roos et al., 1981). We have recently shown this invasion to be inhibited by an antibody against LFA-1, apparently because of its interference with adhesion to the upper surface of the hepatocytes (Roos and Roossien, 1987), suggesting that LFA-1 is important for lymphoma metastasis.

LFA-1 is expressed by leukocytes but not by nonhematopoietic cells (Kürzinger et al., 1981). It was discovered with a monoclonal antibody that inhibited killing by cytotoxic T cells and natural killer cells by interfering with adhesion to the target cell, a step that precedes and is necessary for lethal hit delivery (for review see Martz, 1987). LFA-1 is now known to be involved in many adhesion-related phenomena associated with immune response (Springer et al., 1987). In addition to interleukocyte adhesion, LFA-1 partially mediates binding of activated tumoricidal macrophages to tumor cells (Strassman et al., 1986), and of lymphocytes to endothelial cells (Mentzer et al., 1986), fibroblasts (Dustin et al., 1986), and high endothelium of lymph node postcapillary venules (Pals et al., 1988).

LFA-1 belongs to a family of three leukocyte adhesion proteins, including Mac-1 and p150,95. These are heterodimeric glycoproteins consisting of a unique  $\alpha$  subunit (180, 170, and 150 kD, respectively) noncovalently associated with a common 95-kD  $\beta$  subunit. Both  $\alpha$  and  $\beta$  subunits of this

family show considerable homology with those of the integrins—proteins that mediate adhesion to extracellular matrix components (Hynes, 1987; Kishimoto et al., 1987a; Law et al., 1987). The importance of the LFA-1/Mac-1/p150,95 family of proteins is demonstrated in patients suffering from leukocyte adhesion deficiency, a life-threatening genetic disease (for review see Anderson and Springer, 1987). The leukocytes of these patients are defective in several adhesion-related functions as a result of a deficiency in surface expression of LFA-1, Mac-1, and p150,95. This deficiency originates primarily from defects in the common  $\beta$ -chain (Kishimoto et al., 1987b).

The role of LFA-1 in metastasis might be tested by in vivo administration of anti-LFA-1 antibody. However, such treatment would not only block adhesion of the lymphoma cells but also multiple LFA-1-dependent processes important for both specific and nonspecific host resistance to the tumor cells. In particular, macrophage and natural killer function would be affected. To circumvent this problem, we have generated a set of LFA-1-deficient lymphoma mutant cell lines, and now show that these cells exhibit reduced invasive potential in vitro, as well as attenuated metastatic capacity in vivo.

## Materials and Methods

### Cells and Culture Conditions

Generation and properties of mouse T cell hybridomas were reported elsewhere (Roos et al., 1985). Hybridomas were cultured in RPMI 1640 medium supplemented with 10 mM Hepes, 10% NCTC 135 (Flow Laboratories, Ayleshire, UK), 35 mM NaHCO<sub>3</sub>, 2 mM glutamine, 0.5 mM 2-mer-

captoethanol, 0.5 mM sodium pyruvate, 1 mM oxaloacetic acid, 0.2 IU/ml bovine insulin (Sigma Chemical Co., St. Louis, MO), 1% antibiotic antimycotic solution (Gibco, Daisly, UK), and 10% FCS (Flow Laboratories).

Rat hepatocytes were isolated as described previously (Roos and Van de Pavert, 1982). Cells were cultured in 16-mm multiwell plates (Primaria; Falcon Labware, Oxnard, CA) at  $2 \times 10^5$  cells/well in DME supplemented with 5  $\mu$ g/ml bovine insulin. Before seeding, the wells were coated with 5% newborn calf serum (Sera Laboratories, Sussex, UK) in PBS. After 2 h, the cells were washed twice with DME supplemented with 5  $\mu$ g/ml bovine insulin and 10% newborn calf serum, and cultured overnight in the same medium.

Rat embryo fibroblast 208 F-cells (Müller and Müller, 1984) were cultured in DME supplemented with 10% newborn calf serum, and were used for assays between passages 5 and 15.

## Antibodies

Monoclonal antibodies M17/4, M1/9.3, and M5/49, directed against the LFA-1  $\alpha$ -chain, T-200, and Thy.1, respectively, were kindly donated by Dr. E. Martz (University of Massachusetts). The antibodies were purified from hybridoma supernatant by affinity chromatography on Sepharose-coupled goat anti-rat IgG antibodies, as described before (Roos and Roossien, 1987).

To prepare a polyclonal anti-LFA-1 antiserum, the antigen was purified from TAM2D2 T cell hybridoma cells. Cells ( $5 \times 10^8$ ) were lysed at a density of  $10^7$ /ml in lysis buffer, containing 0.5% NP-40, 4 mM  $MgCl_2$ , 150 mM NaCl, and 40 mM Tris-HCl, pH 7.6, supplemented with protease inhibitors: 1 mM PMSF, 20  $\mu$ g/ml soybean trypsin inhibitor (Sigma Chemical Co.), and 50 Klett U/ml Trasylol (Bayer, Leverkusen, FRG). After 15 min at 4°C, cell debris was removed by a 15-min centrifugation in a minifuge. The lysate was precleared twice with 0.5 ml packed beads of Sepharose CL-4B (Pharmacia Fine Chemicals, Uppsala, Sweden) for 16 and 2 h, respectively. The LFA-1 protein was immunoprecipitated by a 2-h incubation with 0.5 ml packed beads of Sepharose-coupled M17/4 antibody (1 mg antibody/ml beads). The beads were washed with 0.5% NP-40 in 50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 5 mM EDTA, 1 mM PMSF (wash buffer). The antigen was eluted from the beads with 0.5% Triton X-100 in 0.1 M glycine-HCl, pH 2.5, neutralized with 1 M Tris buffer, dialyzed against PBS, and concentrated by Amicon pressure dialysis. Analysis by SDS-PAGE and subsequent silver staining demonstrated that the isolated LFA-1 was highly purified. Rabbits were immunized by intramuscular injection with 100  $\mu$ g of purified LFA-1 in complete Freund's adjuvant and boosted three times with 50–80  $\mu$ g LFA-1 in incomplete Freund's adjuvant. From  $^{125}I$ -surface-labeled TAM2D2 cell lysates, the polyclonal antiserum immunoprecipitated exclusively the LFA-1  $\alpha$  and  $\beta$  subunits of 180 and 97 kD, respectively (not shown). Also from lysates denatured in SDS, both chains were precipitated, showing that the antiserum contained antibodies directed against both subunits.

## Generation and Selection of TAM2D2 Mutants

TAM2D2 cells in culture medium were incubated with 0.4 mg/ml ethyl methanesulfonate for 24 h at 37°C. Cells were centrifuged, suspended in fresh medium, and cultured for 3 d to recuperate from the treatment with the mutagen. Mutants were selected by panning on culture plates coated with M17/4 anti-LFA-1 monoclonal antibody. The plates had been prepared by subsequent incubations with 3% glutaraldehyde (30 min), PBS (1 min), 50  $\mu$ g/ml poly-L-lysine (30 min), and PBS. This sequence of incubations was repeated once, and after a final wash with PBS, the plates were incubated with M17/4 antibody (1.5  $\mu$ g/ml) for 30 min at 20°C, followed by subsequent incubations with 5% BSA in PBS (30 min at 20°C) and culture medium (30 min at 37°C). Mutated cells were incubated on the coated plates for 30 min at 37°C. Nonadhered cells were removed by gently shaking the plates and collecting the upper medium, taking care not to disturb the layer of cells attached to the substrate. Cells were expanded, and the panning procedure was repeated. After 6–10 rounds of selection, the cells were cloned by limiting dilution.

## Biosynthetic Labeling

Cells ( $5 \times 10^6$ ) were pulse-labeled for 60 min at 37°C with 50  $\mu$ Ci of [ $^{35}S$ ]methionine in methionine-free MEM (modified) with Earle's salts (EMEM; Flow Laboratories) supplemented with 10% FCS (dialyzed against PBS). Half of the cells were harvested and stored as a pellet at

–70°C. The remaining cells were diluted with 2 vol of EMEM containing 80  $\mu$ g/ml methionine, chased for 15 h, and stored as a frozen pellet.

## Immunoprecipitations

Labeled cells ( $10^6$ ) were lysed in 0.25 ml lysis buffer. After 15 min on ice, cell debris was removed by a 10-min centrifugation in a minifuge. Lysates were precleared by subsequent incubations with 1  $\mu$ l normal rabbit serum (overnight) and 2  $\mu$ l packed beads of protein A-Sepharose (Pharmacia Fine Chemicals; 30 min). After a 2-h incubation with 2  $\mu$ l rabbit anti-LFA-1 antiserum, the immune complexes were precipitated with 4  $\mu$ l Protein A-Sepharose (30 min). The precipitates were washed five times with wash buffer, after which the immune complexes were eluted with 1.0% Triton X-100 in 0.1 M glycine-HCl, pH 2.5, neutralized with 1 M Tris, 1:1 diluted with twice-concentrated solubilization buffer (Laemmli, 1970), denatured for 5 min at 100°C, and subjected to SDS-PAGE on 7.5% polyacrylamide gels.

## Invasion Assay in Hepatocyte Cultures

Adhesion and invasion were quantitated by light microscopy, as described previously (Roos and Van de Pavert, 1982).  $5 \times 10^5$  tumor cells in 500  $\mu$ l DME were added per hepatocyte culture in a 16-mm well. When anti-LFA-1 antibodies were used (final concentration: 1  $\mu$ g/ml), they were preincubated with the tumor cells for 30 min at 20°C and remained present during incubation with hepatocytes. The cultures were incubated for 4 h at 37°C, washed once with PBS, fixed with glutaraldehyde, dehydrated, and scraped from the dish. The culture fragments were pelleted and embedded in Epon. 1- $\mu$ m-thick sections were stained and observed with a light microscope. Hepatocyte nuclei and infiltrated tumor cells were counted. As a measure of invasion, the infiltration index was calculated (infiltrated tumor cells/hepatocyte nuclei). Measurements were performed at least three times.

## Invasion Assay in Fibroblast Cultures

Invasiveness in fibroblast cultures was quantitated essentially according to the method of Verschuere et al. (1987) and Collard et al. (1987). Tumor cells were washed with PBS, suspended in 25 ml of MEM supplemented with 10 mM Hepes, and incubated, with or without anti-LFA-1 monoclonal antibodies (final concentration: 1  $\mu$ g/ml), for 30 min at 20°C. The cell suspension was then added to confluent rat embryo fibroblast monolayers in 10-cm<sup>2</sup> wells and incubated for 4 h at 37°C and 5% CO<sub>2</sub>. Subsequently, noninfiltrated tumor cells were removed by repeated washing, and the monolayers were fixed with 2% paraformaldehyde in PBS. Infiltrated cells were easily recognized in the phase-contrast microscope as dark and flattened cells. The number of infiltrated cells was counted in 10 different 0.27-mm<sup>2</sup> areas, distributed at random over the monolayers. From this, the number of infiltrated cells per well was calculated, and invasiveness was expressed as the percentage of added cells.

## DNA Analysis

Approximately  $10^5$  cells were fixed with 70% ethanol, treated with 0.1% RNase and 0.1% pepsin (Collard and Smets, 1974), stained with a mixture of ethidium bromide (10  $\mu$ g/ml) and Hoechst 33258 (4  $\mu$ g/ml), and analyzed in a Phye ICP-11 flow cytrophotometer. Trout red blood cells were included as an internal standard. DNA contents were expressed as a percentage of that of BW5147 cells.

## Immunofluorescence Analysis

Cells were washed and resuspended in 50  $\mu$ l PBS containing saturating concentrations of monoclonal antibody. After a 30-min incubation on ice, cells were washed twice with 0.5% BSA in PBS and resuspended in the same buffer containing optimal concentrations of FITC-labeled rabbit anti-rat immunoglobulin (Nordic Immunological Laboratories, Tilburg, The Netherlands). After 30 min on ice, cells were washed twice with 0.5% BSA in PBS and resuspended in 0.5 ml of this buffer. Fluorescence was analyzed with a FACS IV flow sorter (Becton-Dickinson & Co., Sunnyvale, CA).

## Metastatic Potential and Tumorigenicity

Metastatic potential was assessed by injection of  $10^6$  cells into the tail vein of 6–10-wk-old syngeneic AKR mice. Animals were killed when moribund or after 100 d and examined for the presence of metastases. Tumorigenicity

**Table I. Cell Surface Antigens of TAM2D2 T Cell Hybridoma Cells and LFA-1-deficient Mutants**

Cell line	Monoclonal antibody		
	Anti-LFA-1	Anti-T200	Anti-Thy.1
TAM2D2	103.4 (2.0)	313.2	698.2
2B10	3.2 (2.2)	283.9	202.8
1C9	3.0 (2.2)	284.4	2.2
3D1	2.7 (1.9)	177.1	1.9
1A4	2.3 (2.0)	146.4	359.4
3C12	2.4 (2.1)	127.8	372.6

Cells were stained with monoclonal antibodies specific for different cell surface antigens, as described. Fluorescein-coupled rabbit anti-rat immunoglobulin was used as second reagent. Data are expressed in arbitrary units and represent the mean fluorescence detected in the presence of the corresponding monoclonal antibody in a representative experiment. Values in parentheses were obtained with negative control samples by omitting the incubation with monoclonal antibody. The monoclonal antibodies M17/4, M1/9.3, and M5/49 were directed against the mouse antigens LFA-1 ( $\alpha$ -chain), T-200, and Thy.1, respectively.

was tested by subcutaneous injection of  $10^6$  cells in the neck region of AKR mice.

## Results

### Generation of LFA-1-deficient Mutants

Mutation of TAM2D2 T cell hybridoma cells was accomplished by treatment of the cells with the alkylating reagent ethyl methanesulfonate (0.4 mg/ml, 24 h). Initial cell death upon this treatment amounted to 70–90%. Viable cells were expanded and LFA-1-deficient variants were selected on culture plates coated with anti-LFA-1 monoclonal antibody (panning). Nonadhered cells were collected, expanded, and analyzed by immunofluorescence for LFA-1 surface levels; the panning procedure was then repeated. After 6–10 rounds of selection, at least 50% of the cells exhibited substantially reduced LFA-1 levels. After cloning by limiting dilution, we obtained five cell lines on which virtually no LFA-1 was present: 1C9, 2B10, 3D1, 1A4, and 3C12 (Table I). The mutants were screened for T200 and Thy.1 levels; T200 and Thy.1 are two surface antigens which are abundant on parental TAM2D2 cells. Table I shows that the introduced mutations did not result in major changes in the T200 levels. All five mutants exhibited high T200 levels, although those of mutants 3D1, 1A4, and 3C12 were somewhat reduced in comparison with TAM2D2 cells. The observed variability in the T200 levels of the mutants probably originates from clonal variation. Three mutants exhibited high Thy.1 levels, although somewhat lower than TAM2D2 cells, but 1C9 and 3D1 cells were Thy.1 deficient. The growth rates and DNA contents of all mutants were essentially equal to those of TAM2D2 cells (Table II). As will be discussed later, the mutants were derived from at least three distinct mutant clones (Table III): type I (2B10), type II (1C9 and 3D1), and type III (1A4 and 3C12).

### Impaired Synthesis of Either $\alpha$ or $\beta$ Subunit Precursor in Different Mutants

LFA-1  $\alpha$  and  $\beta$  chain synthesis was assayed in pulse-chase

**Table II. Growth Rates and DNA Contents of TAM2D2 T Cell Hybridoma Cells and LFA-1-deficient Mutant Cells**

Cell line	Doubling time	DNA content*
	h	%
TAM2D2	11.7 $\pm$ 0.6	182
2B10	10.9 $\pm$ 2.6	186
1C9	ND	189
1A4	10.1 $\pm$ 0.7	187
3C12	10.7 $\pm$ 1.2	192

The doubling times were calculated from the growth rates of exponentially growing cells. The DNA contents of cells were measured as described. Shown are the data of a representative experiment.


\* DNA contents are expressed as a percentage of that of BW5417 cells.

experiments using [ $^{35}$ S]methionine. For immunoprecipitations a rabbit antiserum was raised against affinity-purified LFA-1. The antiserum immunoprecipitated the  $\alpha/\beta$  complex from NP-40 lysates of  $^{125}$ I-labeled TAM2D2 cells and the individual  $\alpha$  and  $\beta$  subunits from SDS-denatured cell lysates, showing that the antiserum reacted with both subunits (not shown). TAM2D2 parental or mutant cells were pulse-labeled with [ $^{35}$ S]methionine for 1 h and then chased with unlabeled methionine for 15 h. The  $\alpha$  and  $\beta$  chains were immunoprecipitated from NP-40 cell lysates with the rabbit antiserum and Sepharose-coupled protein A. TAM2D2 cells synthesized  $\alpha$  and  $\beta$  chain precursors of 170 and 93 kD, respectively (Fig. 1, A and B, lanes 1). Upon chase, these precursors were converted to the mature 180-kD  $\alpha$  chain and 97-kD  $\beta$  chain (Fig. 1, A and B, lanes 2). A monoclonal antibody against the LFA-1  $\alpha$  chain immunoprecipitated exclusively the  $\alpha$  chain precursor from pulse-labeled cells, whereas the  $\alpha/\beta$  complex was precipitated from chased cells (not shown). In agreement with observations by others (Ho and Springer, 1983; Springer et al., 1984), this demonstrates that the association of the LFA-1  $\alpha$  and  $\beta$  chains occurs upon processing of the precursor forms.

Pulse-chase studies with the obtained set of mutants revealed two different types of mutations leading to LFA-1 deficiency. Mutant cells 1C9, 2B10, and 3D1 did not synthesize detectable amounts of  $\alpha$  chain precursor (Fig. 1 A, lanes 3, 5, and 9, respectively). Although the  $\beta$  chain precursor was produced, the absence of the  $\alpha$  chain precursor prevented its processing to the higher molecular mass mature form, and during the 15-h chase it was degraded (Fig. 1 A, lanes 4, 6, and 8). An opposite type of mutation was found in mutants 1A4 (Fig. 1 B) and 3C12 (not shown); these mutants did not synthesize the  $\beta$  chain precursor although they did synthesize the  $\alpha$  chain precursor (Fig. 1 B, lane 3) which degraded during chase (Fig. 1 B, lane 4).

**Table III. Classification of TAM2D2 Mutant Cell Lines**

Type of mutation	Cell line	Thy.1 surface level	Synthesis of LFA-1 precursors	
			$\alpha$ Subunit	$\beta$ Subunit
Type I	2B10	high	absent	normal
Type II	1C9, 3D1	absent	absent	normal
Type III	1A4, 3C12	high	normal	absent



**Figure 1.** Immunoprecipitation of the LFA-1 subunit precursors from TAM2D2 T cell hybridoma cells and LFA-1-deficient mutants. TAM2D2 and mutant cells were pulse-labeled with [<sup>35</sup>S]methionine for 1 h with or without a 15-h chase, as indicated (*A*: TAM2D2 cells and 1C9, 2B10, and 3D1 mutants; *B*: TAM2D2 cells and 1A4 mutant). The LFA-1  $\alpha$  and  $\beta$  subunits were immunoprecipitated from cell lysates with a rabbit anti-LFA-1 antiserum and protein A-Sepharose. From each lysate an aliquot was incubated with normal rabbit serum and protein A-Sepharose. Representative control immunoprecipitations are shown in lanes 5–8 (*B*). Samples were run on a 7.5% SDS-polyacrylamide gel and subjected to fluorography.  $\alpha'$  and  $\beta'$  indicate the  $\alpha$  and  $\beta$  subunit precursors, respectively. Only the indicated bands represent proteins specifically precipitated by the antiserum.

### Classification of LFA-1-deficient Mutants

Fluorescence analysis (Table I) and pulse-chase studies (Fig. 1) enabled us to divide the obtained set of mutants into three distinct types (Table III). Type I and Type II mutants synthesize the LFA-1  $\beta$  chain precursor, but do not produce the  $\alpha$  chain precursor. Type I mutants have a high Thy.1 expression; type II mutants are Thy.1 deficient. Type III mutants produce the LFA-1  $\alpha$  chain precursor, but do not synthesize the  $\beta$  chain precursor.

### Invasiveness of the Mutants in Hepatocyte Cultures

The invasive potential of parental and mutant cells was assayed *in vitro* in hepatocyte monolayers, as described before (Roos and Van de Pavert, 1982).  $5 \times 10^5$  tumor cells were added to hepatocyte monolayers which had been cultured for 24 h in 16-mm wells. After a 4 h incubation at 37°C, invasion was terminated by glutaraldehyde fixation. The monolayers were dehydrated, scraped off the culture dishes, and embedded in Epon. Sections were cut and stained, and the number of tumor cells infiltrated in the monolayers was counted. Results were expressed as infiltration index, a measure for invasion (for further details, see Materials and Methods; Roos and Van de Pavert, 1982), TAM2D2 cell infiltration of hepatocyte monolayers was inhibited by anti-LFA-1 monoclonal antibody to ~30% of controls (Table IV; Roos and

Roossien, 1987). The invasive potential of each of the three classes of LFA-1-deficient mutants was considerably lower than that of parental cells (Table IV) and comparable to that of parental cells in the presence of an excess of anti-LFA-1 antibody. As expected, this limited invasiveness of the mutants was not further inhibited by the addition of anti-LFA-1 monoclonal antibody.

**Table IV.** Infiltration of TAM2D2 T Cell Hybridoma Cells and LFA-1-deficient Mutants into Hepatocyte Monolayers

Cell line	Infiltration index	
	Anti-LFA-1 monoclonal antibody -	+
TAM2D2	0.79	0.25
2B10 (type I)*	0.26	0.24
1C9 (type II)	0.36	0.30
1A4 (type III)	0.19	0.18
3C12 (type III)	0.20	0.21

TAM2D2 and mutant cell lines, preincubated with M17/4 anti-LFA-1 monoclonal antibody (1  $\mu$ g/ml) where indicated, were incubated for 4 h with hepatocyte monolayers. When cells were pretreated with anti-LFA-1 antibody, the antibody remained present during the incubation with hepatocytes. The infiltration index was determined by counting cells in sections of embedded cultures, as described. Shown are the data for one of several experiments with similar results.

\* Classification of mutants according to Table III.

**Table V. Infiltration of TAM2D2 T Cell Hybridoma Cells and LFA-1-deficient Mutants into Fibroblast Monolayers**

Cell line	Infiltration*	
	Anti-LFA-1 monoclonal antibody	
	-	+
	%	%
TAM2D2	34 ± 6	16 ± 2
2B10 (type I)‡	2 ± 1	1 ± 1
1C9 (type II)	3 ± 1	1 ± 1
1A4 (type III)	4 ± 2	2 ± 1
3C12 (type III)	4 ± 2	2 ± 1

TAM2D2 and mutant cells, preincubated with M17/4 anti-LFA-1 monoclonal antibody (1 µg/ml) where indicated, were incubated for 4 h with rat embryo fibroblast monolayers. The anti-LFA-1-treated cells were incubated with fibroblasts in the presence of the antibody. Infiltrated cells were counted under the phase-contrast microscope.

\* The fraction of infiltrated cells, expressed as a percentage of added cells.

‡ Classification of mutants according to Table III.

### Invasiveness of the Mutants in Fibroblast Monolayers

Recently it was shown that a number of T cell hybridomas, which were invasive in hepatocyte cultures, invade fibroblast monolayers as well (Collard et al., 1987; La Rivière et al., 1988). Invasiveness is easily quantitated in the phase-contrast microscope by counting the number of tumor cells that have infiltrated into the fibroblast monolayers. Parental TAM2D2 cells are highly invasive in these monolayers, and this process is inhibited to ~50% by anti-LFA-1 monoclonal antibody (Table V). In comparison with parental cells, the invasiveness of the LFA-1-deficient mutants was very low. Similar results were obtained with each of the three distinct types of mutants.

### Metastatic Potential of the Mutants

The metastatic potential of TAM2D2 parental and mutant cell lines was tested by intravenous injection of the cells (Table VI). In agreement with earlier results, all animals injected with TAM2D2 cells developed extensive metastasis (Roos et al., 1985). Livers were heavily colonized and enlarged. Extrahepatic metastases were always found in ovaries and kidneys and frequently in lymph nodes, spleen, mesen-

**Table VI. Metastatic Potential of TAM2D2 T Cell Hybridoma Cells and LFA-1-deficient Mutants**

Cell line	Number of mice injected	Moribund animals killed at day	Number of animals that developed metastases*	Location of metastases‡
TAM2D2	11	17-22	11 (100)	L,K,S,O,R
2B10 (type I)§	19	37-43	2 (11)	R (L,K,O)¶
1C9 (type II)	22	37-46	2 (9)	R
1A4 (type III)	10	-	0 (0)	-

AKR mice were injected with 10<sup>6</sup> cells in the tail vein. Moribund animals were killed after the indicated number of days and analyzed for metastases. At day 100 the experiment was terminated.

\* Values in parentheses indicate the percentage of injected animals that developed metastases during the 100-d examination period.

‡ L, liver; K, kidney; S, spleen; O, ovaries; R, retroperitoneal (in the peritoneal cavity behind the kidneys).

§ Classification of mutants according to Table III.

¶ Both animals contained large retroperitoneal tumors. In one animal small tumors were detected in the liver, kidneys, and ovaries.

terium, and in the peritoneal cavity. In contrast, the metastatic potential of the LFA-1-deficient mutants was considerably lower. From each of the three distinct types of mutants, one cell line was tested (Table VI). Only ~10% of the injected animals developed metastases. In most cases a tumor mass was found in the peritoneal cavity behind the kidneys; in one animal small metastases were found in the liver, kidneys, ovaries, and lymphoid organs. The remaining animals survived for at least 100 d, after which no macroscopic metastases were detected. The few metastases originating from the mutant cell lines developed more slowly than those of parental cells (after 37-46 d instead of 17-22). All mutant cell lines were tumorigenic upon subcutaneous injection of cells. Parental cells developed large tumors in all animals after ~12-14 d. Tumors of similar size developed somewhat slower in all animals injected with the mutant cells (i.e., after 18-22 d).

### Discussion

To elucidate invasion mechanisms of metastatic lymphoma cells, we used hepatocyte monolayers as an in vitro model. Lymphoma and T cell hybridoma cells that readily metastasize to the liver extensively invade such monolayers. Recently we found that invasion of hepatocyte monolayers was inhibited by a monoclonal antibody against LFA-1 (Roos and Roossien, 1987). To demonstrate the direct involvement of LFA-1 in metastasis, we generated a set of LFA-1-deficient T cell hybridoma mutants. The reduced invasive and metastatic potential of these mutants provide strong evidence that LFA-1 has an important role in lymphoma metastasis.

The cell line chosen to be mutated was the TAM2D2 T cell hybridoma that exhibits high LFA-1 surface levels and is highly invasive and metastatic (Roos et al., 1985; Roos and Roossien, 1987). Treatment of TAM2D2 cells with the alkylating reagent ethyl methanesulfonate, selection by panning, and subsequent cloning yielded a number of LFA-1-deficient mutants, among which three distinct types could be distinguished (Table III). Type I and II mutants synthesize the precursor of the β chain but not the α chain of LFA-1. In type III mutants the reverse was observed; cells synthesize the precursor of the α subunit but not of the β subunit. Type I and type II mutants differ in Thy.1 expression, which is similar to parental cells on type I but absent on type II mutant cells. Thus, the cell lines obtained were derived from at least three distinct mutant clones.

The invasive potential of parental TAM2D2 cells, quantitated by their infiltration index, was reduced to ~30% in the presence of anti-LFA-1 monoclonal antibody. Since the invasiveness of the mutant cell lines is comparable, this effect of the antibody was apparently not due to steric hindrance or induction of a negative signal (Martz et al., 1983). The reduced but substantial infiltration of the mutants and of parental cells in the presence of anti-LFA-1 antibody shows that LFA-1 is not the only adhesion molecule involved. Inhibition by anti-LFA-1 antibody was previously found to result from a reduction in the number of tumor cells interacting with the hepatocyte monolayers, since the fraction of the reduced number of interacting cells that infiltrated the monolayers during the 4-h test was not diminished (Roos and Roossien, 1987). This indicates that LFA-1 is involved in the initial step of invasion (i.e., in adhesion to the exposed hepatocyte sur-

face) but not in the subsequent actual invasion step, the intrusion between the hepatocytes. In agreement with this conclusion, the reduced invasion of the LFA-1-deficient mutants was also due to decreased LFA-1-dependent adhesion to the hepatocyte monolayers (not shown).

T cell hybridoma cells that invade hepatocyte monolayers also infiltrate rat embryo fibroblast monolayers (La Rivière et al., 1988). The involvement of LFA-1 in the infiltration of such fibroblast cultures is demonstrated by the inhibition of TAM2D2 infiltration in the presence of anti-LFA-1 monoclonal antibody, and the decreased infiltration of the LFA-1-deficient mutant cells (Table V). Because the adhesion of the tumor cells to the monolayers was relatively weak, the adhered tumor cells were removed when the monolayers were washed after incubation, and, therefore, adhesion could not be quantitated. However, in agreement with Dustin et al. (1986), who have shown that pretreatment of lymphocytes with anti-LFA-1 antibody inhibits adhesion to dermal fibroblasts, we assume that the inhibition of the infiltration of TAM2D2 cells in rat embryo fibroblast monolayers also results from the inhibition of adhesion of the tumor cells to the exposed surface of the fibroblasts. As a consequence of this inhibited adhesion, subsequent infiltration of the tumor cells would also be inhibited. The decreased infiltration of the LFA-1-deficient mutants probably originates from their reduced LFA-1-dependent adhesion.

The metastatic potential of the LFA-1-deficient TAM2D2 mutants was ~10-fold lower than that of parental cells (Table VI). Together with the observed reduction in invasive capacity of these mutants, this suggests that LFA-1 is involved in tumor cell metastasis by mediating adhesion to the extravascular surface of the cells in target tissues. Not only metastasis to the liver, but also to kidneys, ovaries, and lymphoid tissues, was reduced, indicating that LFA-1 is also required for efficient invasion into those tissues. This notion is supported by our finding that LFA-1 is also involved in infiltration of TAM2D2 T cell hybridoma cells into fibroblast monolayers.

Because anti-LFA-1 monoclonal antibody inhibits not only the invasiveness of TAM2D2 T cell hybridoma cells, but also of spontaneously arisen highly metastatic MB6A lymphoma cells (Roos and Roossien, 1987), we suggest a similar role for LFA-1 in the metastasis of the latter cells. We are currently investigating the LFA-1 cell surface expression of a number of lymphoma cells. Until now, at least two highly metastatic lymphomas (i.e., ESb [Schirrmacher et al., 1979] and MDAY-D2 [Kerbel et al., 1978]) were found to express the antigen (not shown). Probably LFA-1 is generally involved in the metastasis of highly metastatic lymphomas.

Recently, we found within a set of different T cell hybridomas a close correlation between invasive potential, quantitated by the infiltration index (I) measured in hepatocyte cultures, and metastatic potential (La Rivière et al., 1988). Low-invasive cells ( $I < 0.13$ ) were not metastatic, whereas highly invasive cells ( $I = 0.53-2.08$ ) caused widespread metastasis. Intermediately invasive cells ( $I = 0.13-0.45$ ) formed metastases in only a limited number of animals, predominantly extrahepatically, mostly in lymphoid tissues. It is striking to note that this classification also holds for the presently described mutants. Based on their infiltration index ( $I = 0.18-0.30$ ), they belong to the intermediately invasive group, and they caused metastases in a limited number of animals, mainly at an extrahepatic site. Taken together, this

suggests that a certain threshold level of invasiveness is required for widespread metastasis of this type of tumor cell.

Probably the mutant cell lines described harbor more mutations than the one affecting LFA-1 synthesis. This is evident for type II mutants which are also deficient in Thy.1. For two reasons, it is unlikely that the change in invasive and metastatic potential is caused by such additional mutations. First, because the reduction is similar for three distinct mutants that probably do not carry identical additional mutations. Second, because all mutants, irrespective of class, infiltrate hepatocyte monolayers to the same extent as parental cells in the presence of anti-LFA-1 antibody.

Recently, cloning of the human LFA-1  $\beta$  gene has been described (Kishimoto et al., 1987a; Law et al., 1987). We are presently attempting to transfect this gene into a type III LFA-1-deficient mutant, in which  $\beta$  chain precursor synthesis is absent. This should result in a transfectant that produces LFA-1  $\alpha$  and  $\beta$  chain precursors from mouse and human origin, respectively. It has been demonstrated that such precursors are able to associate and mature to a human/mouse interspecies LFA-1 that is expressed on the cell surface (Marlin et al., 1986). If this LFA-1 species is functional, the behavior of such a transfectant will hopefully provide definite proof that the reduced invasive potential in vitro and metastatic capacity in vivo of the mutants are due to LFA-1 deficiency.

We are grateful to Ilja Van de Pavert for providing excellent technical assistance, and to Nico Ong for preparing the figures.

This work was supported by grant 85-6 from the Koningin Wilhelmina Fonds/Netherlands Cancer Research Foundation.

Received for publication 21 October 1988 and in revised form 2 January 1989.

## References

- Anderson, D. C., and T. A. Springer. 1987. Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. *Annu. Rev. Med.* 38:175-194.
- Collard, J. G., and L. A. Smets. Effect of proteolytic inhibitors on the growth and surface architecture of normal and transformed cells. *Exp. Cell Res.* 86:75-80.
- Collard, J. G., M. Van de Poll, A. Scheffer, E. Roos, A. H. M. Hopman, A. H. M. Geurts van Kessel, and J. J. M. Van Dongen. 1987. Location of genes involved in invasion and metastasis on human chromosome 7. *Cancer Res.* 47:6666-6670.
- Dustin, M. L., R. Rothlein, A. T. Bhan, C. A. Dinarello, and T. A. Springer. 1986. Induction by IL-1 and interferon, tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). *J. Immunol.* 137:245-254.
- Ho, M.-K., and T. A. Springer. 1983. Biosynthesis and assembly of the alpha and beta subunits of Mac-1, a macrophage glycoprotein associated with complement receptor function. *J. Biol. Chem.* 258:2766-2769.
- Hynes, R. O. 1987. Integrins: a family of cell surface receptors. *Cell.* 48:549-554.
- Kerbel, R. S., R. R. Twiddy, and D. M. Robertson. 1978. Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain. *Int. J. Cancer.* 22:583-594.
- Kishimoto, T. K., K. O'Connor, A. Lee, T. M. Roberts, and T. A. Springer. 1987a. Cloning of the  $\beta$  subunit of the leukocyte adhesion proteins: homology to an extracellular matrix protein defines a novel supergene family. *Cell.* 48:681-690.
- Kishimoto, T. K., N. Hollander, T. M. Roberts, D. C. Anderson, and T. A. Springer. 1987b. Heterogeneous mutations in the  $\beta$  subunit common to the LFA-1, Mac-1 and p150,95 glycoproteins cause leukocyte adhesion deficiency. *Cell.* 50:193-202.
- Kürzinger, K., T. Reynolds, R. N. Germain, D. Davignon, E. Martz, and T. A. Springer. 1981. A novel lymphocyte function-associated antigen (LFA-1): cellular distribution, quantitative expression, and structure. *J. Immunol.* 127:596-602.
- Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of

- the head of bacteriophage T4. *Nature (Lond.)* 227:680-685.
- La Rivière, G., C. A. Schipper, J. G. Collard, and E. Roos. 1988. Invasiveness in hepatocyte and fibroblast monolayers and metastatic potential of T-cell hybridomas in mice. *Cancer Res.* 48:3405-3410.
- Law, S. K. A., J. Gagnon, J. E. K. Hildreth, C. E. Wells, A. C. Willis, and A. J. Wong. 1987. The primary structure of the  $\beta$  subunit of the cell surface glycoproteins LFA-1, CR3 and p150,95 and its relationship to the fibronectin receptor. *EMBO (Eur. Mol. Biol. Organ.) J.* 6:915-919.
- Marlin, S. D., C. C. Morton, D. C. Anderson, and T. A. Springer. 1986. LFA-1 immunodeficiency disease: definition of the genetic defect and chromosomal mapping of  $\alpha$  and  $\beta$  subunits of the Lymphocyte Function-associated Antigen 1 (LFA-1) by complementation in hybrid cells. *J. Exp. Med.* 164:855-867.
- Martz, E. 1987. LFA-1 and other accessory molecules functioning in adhesions of T and B lymphocytes. *Hum. Immunol.* 18:3-37.
- Martz, E., W. Heagy, and S. H. Gromkowski. The mechanism of CTL-mediated killing: monoclonal antibody analysis of the roles of killer and target-cell membrane proteins. *Immunol. Rev.* 72:73-96.
- Mentzer, S. J., S. J. Burakoff, and D. V. Faller. Adhesion of T lymphocytes to human endothelial cells is regulated by the LFA-1 membrane molecule. *J. Cell. Physiol.* 126:285-290.
- Müller, R., and D. Müller. 1984. Cotransfection of normal NIH/3T3 DNA and retroviral LTR sequences: a novel strategy for the detection of potential c-onc genes. *EMBO (Euro. Mol. Biol. Organ.) J.* 3:1121-1127.
- Pals, S. T., A. Den Otter, F. Miedema, P. Kabel, G. D. Keizer, R. J. Scheper, and C. J. L. M. Meijer. 1988. Evidence that leukocyte function-associated antigen-1 is involved in recirculation and homing of human lymphocytes via high endothelial venules. *J. Immunol.* 140:1851-1853.
- Roos, E., I. V. Van de Pavert, and O. P. Middelkoop. 1981. Infiltration of tumor cells into cultures of isolated hepatocytes. *J. Cell Sci.* 47:385-397.
- Roos, E., and I. V. Van de Pavert. 1982. Effect of tubulin-binding agents on the infiltration of tumor cells into primary hepatocyte cultures. *J. Cell Sci.* 55:233-245.
- Roos, E., G. La Rivière, J. G. Collard, M. J. Stukart, and P. De Baetselier. 1985. Invasiveness of T-cell hybridomas in vitro and their metastatic potential in vivo. *Cancer Res.* 45:6238-6243.
- Roos, E., and F. F. Roossien. 1987. Involvement of leukocyte function-associated antigen-1 (LFA-1) in the invasion of hepatocyte cultures by lymphoma and T-cell hybridoma cells. *J. Cell Biol.* 105:553-559.
- Schirmacher, V., G. Shantz, K. Clauer, D. Komitowski, H. P. Zimmermann, and M. L. Lohmann-Matthes. 1979. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice: tumor invasiveness in vitro and metastasis formation in vivo. *Int. J. Cancer.* 23:233-244.
- Springer, T. A., W. S. Thompson, L. J. Miller, F. C. Schmalstieg, and D. C. Anderson. 1984. Inherited deficiency of the Mac-1, LFA-1, and p150,95 glycoprotein family and its molecular basis. *J. Exp. Med.* 160:1901-1918.
- Springer, T. A., M. L. Dustin, T. K. Kishimoto, and S. D. Marlin. 1987. The lymphocyte function-associated LFA-1, CD-2, and LFA-3 molecules: cell adhesion receptors of the immune system. *Annu. Rev. Immunol.* 5:223-252.
- Strassman, G., T. A. Springer, S. D. Somers, and D. O. Adams. 1986. Mechanisms of tumor cell capture by activated macrophages: evidence for involvement of lymphocyte function-associated (LFA)-1 antigen. *J. Immunol.* 136:4328-4333.
- Verschueren, H., D. Dekegal, and P. De Baetselier. 1987. Development of a monolayer invasion assay for the discrimination and isolation of metastatic lymphoma cells. *Invasion & Metastasis.* 7:1-15.